Dyne Therapeutics Inc Ordinary Shares DYN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Novartis's failed trial for cholesterol drug leads to broad biopharma stock selloff
-
Why the Dow is being dragged down by a Swiss company's bad news
-
Dyne Therapeutics Shares Rise After Amendment to Debt Facility
-
This biotech's stock soared as investors look for the next buyout target
-
Dyne Therapeutics Shares Rise After Novartis Reaches Deal to Buy Avidity
Trading Information
- Previous Close Price
- $15.82
- Day Range
- $15.09–16.03
- 52-Week Range
- $12.33–27.31
- Bid/Ask
- $15.28 / $15.52
- Shares Outstanding
- 186.75M
- Market Cap
- $2.84B
- Volume/Avg
- 3M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 258
- Website
- https://www.dyne-tx.com
Valuation
|
Metric
|
DYN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.73 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
DYN
Financial Strength
|
Metric
|
DYN
|
|---|---|
Quick Ratio | 11.51 |
Current Ratio | 12.02 |
Interest Coverage | −36.06 |
Quick Ratio
DYN
Profitability
|
Metric
|
DYN
|
|---|---|
Return on Assets (Normalized) | −48.29% |
Return on Equity (Normalized) | −61.68% |
Return on Invested Capital (Normalized) | −52.90% |
Return on Assets
DYN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|r^?xQXf | LOCK|W&>wD | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|xNGwB@y | LOCK|>Q<P | $76B | |||
| Moderna Inc
MRNA
| LOCK|cqVJx? | LOCK|k# | $75B | |||
| argenx SE ADR
ARGX
| LOCK|Rmz?Pbp | LOCK|pyv | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|v>$fFX | LOCK|Xd | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|l?#%@FZ | LOCK|&??% | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@@&TKMW | LOCK|<!wtR | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|k!V@h# | LOCK|!x | $24B | |||
| Incyte Corp
INCY
| LOCK|D%PxgY | LOCK|rQ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|>Dtw@< | LOCK|CSM | $15B |
United States